IRulya Therapeutics Inc. — Form 8-K
Filed October 19, 2026 · analyzed by the 8-K Agent
8-K
▲ Likely positive
significance 62/100
What the filing says
IRulya (formerly Quince Therapeutics, $64M market cap) released Phase 2a data for LAM-001, an inhaled rapamycin formulation, in 10 patients with pulmonary hypertension (6 PH-ILD subgroup): 6MWD improved +67.4m, PVR declined -35.3% (exercise), NT-proBNP fell -28.8%, 100% of completers improved WHO functional class by week 24, with minimal adverse events (2 cases mild cough, 1 gingivitis). Phase 2b PH-ILD trial (75 patients, data 1Q 2028) and Phase 2 BOS trial (19 patients fully enrolled, data 1Q 2027) are underway; SAPH Phase 2 (60 patients) anticipated to start 4Q 2026. Company raised $115M in May 2026 financing.
Why this rating
Early efficacy signals in orphan indications with unmet need; 75-patient Phase 2b underway represents material pipeline advancement. Magnitude of $115M raise is ~180% of market cap—transformational capital event. Relative to $64M company, this is meaningful but early-stage; clinical data still preliminary in small cohorts. Positive efficacy/safety profile reduces near-term risk but regulatory path remains multi-year.
See more from October 19, 2026.
EDGAR·FLOW summarizes public SEC EDGAR filings with automated analysis. Materiality scores and stock-impact predictions are algorithmically generated and are not investment advice. Always verify against the source filing on SEC.gov.